• October 22, 2020 

    Malignant Melanoma Treatment & ManagementBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    The dramatic array of treatment options now available for this serious disease is nicely summarized in this review. (Free registration required, written with a physician audience in mind.)

    .

  • October 22, 2020 

    Cervical Cancer—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD.

    Cervical cancer can be detected early, but when it is fully developed it requires advanced treatment approaches. This comprehensive review outlines treatment options. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020 

    Hepatocellular Carcinoma (HCC)—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020 

    Acute Myeloid Leukemia (AML)—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020 

    Lymphoblastic Lymphoma—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2019 comprehensive presentation of lymphoblastic (precursor B-cell and T-cell) lymphoma emphasizes lymph node-predominant involvement in this blood-lymph node diaspora. (Free registration required, written with a physician audience in mind.)

    .

  • October 16, 2020 

    Hodgkin Lymphoma—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic approach to a potentially curable form of lymphoma is richly detailed and specific for all types and stages of Hodgkin lymphoma. (Free registration required, written with a physician audience in mind.)

    .

  • October 10, 2020 

    Novel Developments in the Multimodality Treatment of Esophageal CancerBookmark

    George Lundberg, MD

    A special issue of the research journal Annals of Esophagus curated by Contributing Editor George Lundberg, MD.

    This special issue of an academic research journal discusses “multimodality” treatment—the combination of more than one treatment—and how it is used to treat advanced esophageal cancer.

    .

  • October 8, 2020 

    First Approval of Second-Line Therapy for DLBCLBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The FDA has granted accelerated approval to tafasitamab (brand name Monjuvi) as a second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), based upon overall responses seen in a clinical trial. This is the first FDA approval of a second-line treatment for this condition. There are few, if any, other options.

    .

  • October 8, 2020 

    Oral Azacitidine Wins FDA Approval for AMLBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  • October 8, 2020 

    Raising the Bar for Myelofibrosis Therapy DevelopmentBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    Myelodysplastic syndrome (MDS) commonly occurs before a patient develops acute leukemia, and is largely unresponsive to therapy. Two new clinical trials are entering phase 3 and may offer some hope.

    .